Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Accounts Payables (2021 - 2026)

Axsome Therapeutics' Accounts Payables history spans 6 years, with the latest figure at $106.7 million for Q1 2026.

  • On a quarterly basis, Accounts Payables rose 24.57% to $106.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $106.7 million, a 24.57% increase, with the full-year FY2025 number at $65.5 million, down 55.71% from a year prior.
  • Accounts Payables hit $106.7 million in Q1 2026 for Axsome Therapeutics, up from $65.5 million in the prior quarter.
  • Over the last five years, Accounts Payables for AXSM hit a ceiling of $148.0 million in Q4 2024 and a floor of $12.6 million in Q1 2022.
  • Historically, Accounts Payables has averaged $66.5 million across 5 years, with a median of $64.3 million in 2024.
  • Biggest five-year swings in Accounts Payables: skyrocketed 510.79% in 2023 and later tumbled 55.71% in 2025.
  • Tracing AXSM's Accounts Payables over 5 years: stood at $51.6 million in 2022, then skyrocketed by 75.28% to $90.5 million in 2023, then skyrocketed by 63.52% to $148.0 million in 2024, then crashed by 55.71% to $65.5 million in 2025, then soared by 62.81% to $106.7 million in 2026.
  • Business Quant data shows Accounts Payables for AXSM at $106.7 million in Q1 2026, $65.5 million in Q4 2025, and $54.2 million in Q3 2025.